By Chris Wack
BioCryst Pharmaceuticals shares were down 12% to $8.08 after the company reported a fourth-quarter loss that was wider than expected.
The stock hit its 52-week high of $9.50 Friday, and is up 42% in the past 12 months.
The biotechnology company said it had a quarterly loss of $26.8 million, or 13 cents a share, compared with a loss of $61.7 million, or 31 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $13 million, or five cents a share.
Revenue for the quarter was $131.5 million, compared with last year's $93.4 million and the $130.1 million analysts were expecting.
The company said quarterly revenue for Orladeyo, its treatment for the prevention of hereditary angioedema attacks, was $124.2 million, 36.6% higher than last year.
BioCryst increased its 2025 revenue guidance for Orladeyo to $535 million to $550 million, from its previous estimate of $515 million to $535 million.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 24, 2025 10:59 ET (15:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。